U.S., May 7 -- ClinicalTrials.gov registry received information related to the study (NCT06958796) titled 'Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)' on April 18.
Brief Summary: This study is being done to find out if administering CytoGam(R) after the end of standardly prescribed preventive antiviral treatment can help transplant recipients with a high risk for developing late CMV disease after a liver and/or kidney transplant.
Study Start Date: May 15
Study Type: INTERVENTIONAL
Condition:
Cytomegalovirus
Organ Transplant
Kidney Transplant; Complications
Liver Transplant Complications
Simultaneous Liver-Kidney Transplantation; Complications
Intervention:
DRUG: Cytomegalovirus Immune Globulin In...